Drug Profile
EL 715
Latest Information Update: 12 Nov 2003
Price :
$50
*
At a glance
- Originator Elan Corporation
- Class Antipsoriatics; Osteoporosis therapies; Vitamins
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis; Psoriasis
Most Recent Events
- 18 May 2001 Profile reviewed but no significant changes made
- 06 Nov 1998 No-Development-Reported for Postmenopausal osteoporosis in USA (PO)
- 06 Nov 1998 No-Development-Reported for Psoriasis in USA (Topical)